Kornimate/medical-research-clean huggingface dataset:
cbd for pain reduction and opioid use after ankle and tibia fracture orif

Conditions: Ankle Fractures; Tibia Fracture

Summary: the purpose of this study is to evaluate the effects of administering cbd to control post-operative pain in patients undergoing ankle fracture open reduction and internal fixation, tibial plafond (pilon) open reduction and internal fixation, tibial shaft repair (open reduction internal fixation or intramedullary nail fixation), or tibial plateau open reduction and internal fixation. secondly, the purpose is to evaluate the effectiveness of cbd in comparison with opioid therapy for post-operative pain.


Eligibility criteria:
inclusion criteria: * patients undergoing an ankle fracture open reduction and internal fixation (medial malleolus, lateral malleolus, posterior malleolus, and/or syndesmosis repair), tibial plafond (pilon) open reduction and internal fixation, tibial shaft repair (open reduction internal fixation and intramedullary nail fixation), or tibial plateau open reduction and internal fixation * patients ages 18-75, inclusive * female patients must be currently practicing effective forms of two types of birth control, which are defined as those, alone or in combination, that result in a low failure rate (less than 1% per year) when used consistently and correctly * male patients must be using an effective form of contraception exclusion criteria: * legally incompetent or mentally impaired (e.g., minors, alzheimer's subjects, dementia, etc.) * younger than 18 years of age * older than 75 years of age * any patient considered a vulnerable subject: pregnant women or fetuses, children, cognitively impaired adults, prisoners * history of cannabis abuse or dependence * history of coagulation abnormalities and thromboembolic disease or current abnormal coagulation test values * history of stroke or acute coronary syndromes within 3 months before surgery * abnormal coagulation profile * renal failure (serum creatinine \> 250 μmol/l \[2.83 mg/dl\]) or liver cirrhosis * patients that have been on pre-operative opioid management for any reason * patients meeting the dsm-v for major psychiatric illness, such as bipolar disorder * patients diagnosed with major depression, psychosis, or substance abuse disorder * patients with current or a history of suicidal ideation * breastfeeding females * patients with clinically significant illness, including cardiovascular disorders * clinically significant lab abnormalities * abnormal lfts * patients with major neurological disorders, such as dementia, parkinson's disease, cognitive impairment, epilepsy, history of traumatic brain/head injury, or seizures * patients with moderate (child-pugh b) and severe hepatic impairment (child-pugh c). * patients taking moderate or strong inhibitors of cyp3a4 and cyp2c19 concomitantly * patients taking strong cyp3a4 and cyp2c19 inducers concomitantly

Keywords: cannabidiol
disability and quality of life in patients with lymphatic filariasis in rural southern india

Conditions: Lymphatic Filariasis

Summary: according to the world health organization, lymphatic filariasis, a mosquito-borne parasitic disease, is the second leading cause of disability worldwide. across 81 countries, approximately 120 million people are infected with the disease, and of those infected, an estimated 40% reside in india alone. the most disfiguring symptoms of lymphatic filariasis, elephantiasis and lymphedema, cause long-term suffering in patients who are then often embarrassed or even rejected from their communities. because of the disease's debilitating physical and social effects on patients, this study will explore the intersection of disability and health-related quality of life (hrqol) in lymphatic filariasis patients in india. specifically, hrqol and disability in lymphatic filariasis subjects and age- and gender- matched control subjects will be compared. two hrqol tools , the general dermatology life quality index (dlqi) and a disease-specific instrument developed by a dermatology group in india will be used to gauge hrqol. in addition, the demographic and disease-specific factors associated with hrqol and disability in filarial lymphedema subjects will be identified.


Eligibility criteria:
case inclusion criteria * subjects with a clinical diagnosis of lymphatic filariasis * subjects over the age of 18 and able to give consent case exclusion criteria * subjects on active treatment for lymphatic filariasis * subjects who are under the age of 18 or unable to give informed consent control inclusion criteria * subjects without a clinical diagnosis of lymphatic filariasis * subjects over the age of 18 and able to give consent control exclusion criteria * subjects without a clinical diagnosis of lymphatic filariasis * subjects who are under the age of 18 or unable to give informed consent
peripheral stem cell transplantation following radiation therapy in treating patients with hodgkin's disease or non-hodgkin's lymphoma

Conditions: Lymphoma

Summary: rationale: drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. purpose: phase ii trial to study the effectiveness of chemotherapy followed by peripheral stem cell transplantation in treating patients who have hodgkin's disease or non-hodgkin's lymphoma.

objectives: i. determine the toxicity and response to intensive chemotherapy followed by autologous peripheral blood stem cell transplantation in patients with hodgkin's disease or non-hodgkin's lymphoma who have received prior chemotherapy and/or radiotherapy. outline: patients receive oral busulfan every 6 hours on days -9 to -6 and cyclophosphamide iv over 2 hours on days -5 to -2. autologous peripheral blood stem cells are reinfused on day 0. patients are followed monthly for 1 year. projected accrual: not specified

Eligibility criteria:
disease characteristics: histologically proven hodgkin's disease or histologically proven non-hodgkin's lymphoma (nhl) intermediate grade or large cell immunoblastic (high grade) refractory to standard therapy or relapsed following initial complete remission must have received radiotherapy to the extent that no longer eligible for involved field radiation, cyclophosphamide, or total body irradiation no cns disease a new classification scheme for adult non-hodgkin's lymphoma has been adopted by pdq. the terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. however, this protocol uses the former terminology. patient characteristics: age: physiologic 65 and under performance status: ecog 0-2 life expectancy: at least 2 months hematopoietic: not specified hepatic: not specified renal: creatinine less than 1.5 mg/dl or creatinine clearance greater than 50 ml/min cardiovascular: no active heart disease no congestive heart failure no myocardial infarction in the last 3 months no significant arrhythmia requiring medication pulmonary: no significant nonneoplastic pulmonary disease no chronic obstructive pulmonary disease diffusing capacity at least 50% predicted or fev1 and/or fvc at least 75% predicted (unless due to nhl or hodgkin's disease) other: hiv negative no clinical evidence of aids prior concurrent therapy: biologic therapy: not specified chemotherapy: see disease characteristics endocrine therapy: not specified radiotherapy: see disease characteristics surgery: not specified

Keywords: recurrent adult hodgkin lymphoma childhood immunoblastic large cell lymphoma recurrent/refractory childhood hodgkin lymphoma recurrent grade 3 follicular lymphoma recurrent adult diffuse small cleaved cell lymphoma recurrent adult diffuse mixed cell lymphoma recurrent adult diffuse large cell lymphoma recurrent adult immunoblastic large cell lymphoma
ascension® post- approval study; pyrocarbon metacarpophalangeal total joint prosthesis

Conditions: Rheumatoid Arthritis; Systemic Lupus Erythematosus; Osteoarthritis; Post-traumatic Arthritis

Summary: this study is a non-randomized, consecutive enrollment, one-year post-approval study of patients who are treated with the ascension® mcp.


Eligibility criteria:
inclusion criteria: * indications consistent with the fda approved indications for use: index, long, ring, or small finger metacarpophalangeal (mcp) joints that exhibit symptoms of pain, limited motion, or inadequate bony alignment (i.e., subluxation/dislocation) secondary to articular destruction or degenerative disease related to rheumatoid arthritis, systemic lupus erythematosus, osteoarthritis, or post-traumatic arthritis where soft tissue reconstruction can provide adequate stabilization * willing to participate in the study * signed an informed consent form * the means and ability to return for all required study visits * are not transient exclusion criteria: patients who have any of the following contraindications will be excluded from the study: * inadequate bone stock at the implantation site * active infection in the mcp joint * nonfunctioning and irreparable mcp musculotendinous system * physical interference with or by other prostheses during implantation or use * procedures requiring modification of the prosthesis * skin, bone, circulatory and/or neurological deficiency at the implantation site

Keywords: arthritis rheumatoid arthritis systemic lupus erythematosus osteoarthritis autoimmune diseases connective tissue diseases immune system diseases joint diseases musculoskeletal diseases rheumatic diseases
glutamine pet imaging in lam

Conditions: Lymphangioleiomyomatosis (LAM)

Summary: in this study, subjects with spontaneous or tuberous sclerosis complex associated lymphangioleiomyomatosis (lam) who have not been started on therapy with mtor inhibitors such as sirolimus or everolimus to undergo a pet/ct scan using an novel pet tracer that may better evaluate disease activity in lam subjects both before and after the initiation of mtor inhibitor therapy will be enrolled. the procedure for each scan will be similar, involving one administration of the novel tracer c11-glutamine followed by a whole body pet/ct scan.

objectives this is a hypothesis-driven prospective pilot study of the targeted pet reagent 11c-glutamine in lam. the objective is to test the hypothesis that 11c-glutamine pet/ct will demonstrate uptake within the lungs and/or associated neoplasm of patients with lam and that this effect will be modified by treatment with mtor inhibitors. rationale our rationale is that 11c-glutamine pet/ct may provide an improved ability to diagnose lam, as well as predict and monitor treatment response to mtor inhibitors. aims test the hypothesis that 11c-gln pet imaging of the lungs in humans will reflect the known "glutamine addiction" seen in mechanistic preclinical studies of lam. as a result, pet imaging will show increased tracer uptake in affected areas of diseased lungs and will show reduced uptake after initiating treatment with mtor inhibitors. approach: we will evaluate 11c-glutamine pet/ct uptake in patients with known lam, and if possible, we will test subjects again after 8 weeks of mtor inhibitor therapy (either sirolimus or everolimus).

Eligibility criteria:
inclusion criteria: 1. female subjects 2. ≥ 18 years of age 3. diagnosis of lam via either a. histopathologic diagnosis b. compatible ct chest and one of the following i. tuberous sclerosis complex\* ii. angiomyolipoma or lymphangioma iii. chylous effusion iv. serum vegf-d level \>800 pg/ml * the diagnosis of tsc will be based on the presence of at least two major criteria or one major and one or more minor features per published guidelines.(30) exclusion criteria: 1. patients with any known intrathoracic cancer (primary lung cancer or metastatic disease) or undergoing active treatment for malignancy 2. patients with use of investigational therapies for lam either currently or in the prior 3 months 3. patients with body weight ≥400 pounds or body habitus or disability that will not permit the imaging protocol to be performed 4. patients known to be pregnant or breastfeeding 5. patients with clinically active known or suspected pulmonary infection of any type 6. patients known or suspected to have any inborn error of metabolism 7. patients with known type i diabetes mellitus 8. patients who cannot have a peripheral iv for any reason 9. patients who cannot lie flat for the duration of the pet scan 10. patients who are claustrophobic 11. patients with a prior allergy to contrast agents or to pet tracers
evolution of the patient's perception of the use of the upper limb after a stroke during intensive rehabilitation

Conditions: Upper Limb Ischemia

Summary: this study is being carried out in the context of rehabilitation after stroke, where persistent upper limb weakness is a major challenge. it aims to explore the relationship between observed function and patients' perceived participation in use.


Eligibility criteria:
inclusion criteria: * first stroke as defined by the world health organization. * upper limb paresis with a nihss national institutes of health stroke scale score \> or = 1/4 for upper limb motor function exclusion criteria: * life expectancy \<12 months * inability to understand french. * pre-existing severe multiple disability affecting arm function. * presence of pre-existing central neurological pathologies. * mini-mental state examination \< 21
treatment of refractory auditory verbal hallucinations with tdcs in schizophrenia

Conditions: Schizophrenia

Summary: the purpose of this study is to exploratively evaluate the efficacy and safety of transcranial direct current stimulation (tdcs) in patients with schizophrenia who experience persistent auditory verbal hallucinations after adequate antipsychotics therapy for over three months.


Eligibility criteria:
inclusion criteria: * patients with schizophrenia by the diagnostic and statistical manual of mental disorders, fourth edition, text revision (dsm-iv-tr) * presence of auditory hallucination after three months' trial of antipsychotics of adequate dose * the hamilton program for schizophrenia voices questionnaire (hpsvq) score is at least 8 exclusion criteria: * significant brain pathology including head trauma, seizure, meningitis * intellectual disability (iq \< 70) * severe personality disorder * substance use disorder (except nicotine) * severe medical illness * disability in the sensory organs * pregnancy

Keywords: schizophrenia refractory auditory hallucination tdcs
evaluation of the feasibility of using augmented reality in laparoscopic surgery, by a clinical study during gynecological laparoscopic surgical procedures. (endora2)

Conditions: Myoma;Uterus; Adenomyoma of Uterus

Summary: augmented reality is a technology that allows surgeons to superimpose virtual images from preoperative imaging onto the endoscopic vision system intraoperatively. the goal of this clinical trial is to demonstrate that the use of augmented reality during laparoscopic gynecological surgery with a dedicated device could provide assistance to the surgeon, in terms of technical comfort and better visualization of the benign tumor to be resected on a mobile organ.


Eligibility criteria:
inclusion criteria: * aged between 18 (included) and 84 (included), * patient with intrauterine myoma, with indication for surgical management by laparoscopic myomectomy, or uterine pathology with indication for surgical management by laparoscopic hysterectomy, * patient affiliated or beneficiary of a health insurance scheme, * patient agreeing to participate in the study after having received the written information document and signed the consent form. exclusion criteria: * patients under 18 or over 84 years of age, * patients with contraindications to mri (pacemaker, ocular metal splinters, etc.), * impossibility of planned surgery, * patient with endometrial cancer contraindicating laparoscopic surgery, * known pregnant or breast-feeding patient, * patient of legal age, under guardianship or curatorship, * patients whose regular follow-up is impossible for geographical, psychological, family or social reasons (these reasons will be collected).

Keywords: augmented reality laparoscopic surgery uterine myomectomy uterine adenomyomectomy hysterectomy minimally invasive surgery
treatment and prevention of traditional chinese medicines (tcms) on covid-19 infection

Conditions: Pneumonia Caused by Human Coronavirus (Disorder)

Summary: the aim of this study is to test whether traditional chinese medicines (tcms) are effective and safe for treating covid-19 infection. after the enrolment of approximately 30 subjects, the recruitment will be paused, and planned interim analysis will be performed to preliminarily investigate the efficacy and safety of tcms in patients infected with covid-19.

in december 2019, a cluster of patients with pneumonia in wuhan, china, was caused by a novel betacoronavirus, which named the 2019 novel coronavirus (covid-19). it was frequently reported that covid-19 could be a public health crisis with high infectiousness, and it naturally spread across the country. most of patients with covid-19 infection were found to have non-specific symptoms including fever, cough, myalgia and fatigue. in addition, some patients were more likely to develop severe respiratory illness similar to severe acute respiratory syndrome (sars), or even die. however, there was no timely and effective treatment of patients with covid-19 infection. traditional chinese medicines (tcms), are derived from plants and usually incorporate one or more herbs as the basic drug(s) to treat the disease. an rct was performed to investigate tcm was effective and safe for treating covid-19 infection. eligible subjects will be randomized in a 1:1 ratio, and 1 subject on conventional medicines and tcms granules for every 1 subject on conventional medicines. according to recommendations for prevention and control of pneumonia cause by covid-19 infection from china national health commission, conventional medicines involve oxygen therapy and antiviral therapy (alfa interferon via aerosol inhalation, and lopinavir/ritonavir, p.o). additionally, planned interim analysis will be performed, because the prevention and control of covid-19 infection might affect estimated enrollment.

Eligibility criteria:
inclusion criteria: * confirmed covid-19 infection case in term of laboratory evidence; * 80 years ≥ age ≥ 14years; * within 72 hours after the onset of abnormalities shown by chest radiology or several symptoms (fever and cough). exclusion criteria: * age \ 80 years; * pregnant or lactating female; * one of the following items occurred at the enrollment: (i) respiratory failure necessitating mechanical ventilation; (ii) liver failure: total bilirubin ≥ 10mg/dl and/or severe coagulation disorders; (iii) renal function failure: although adequate circulating blood and cardiac output, urine ≤ 0.5ml/kg·h, cr or bun ≥ 1.5 times normal elevation; * intake of chinese medicinal herbs during the past 2 weeks; * refused to sign an informed consent form prior to study participation; * unwilling and unable to comply with protocol request.
evaluation of perioperative management of curative anticoagulants in the geriatric perioperative unit in patient hospitalized for femoral neck fracture.

Conditions: Anticoagulants; Circulating, Hemorrhagic Disorder; Femoral Neck Fractures

Summary: pilot study to evaluate the management of curative anticoagulant prescriptions pre- and postoperatively in elderly patients hospitalized for femoral neck fracture.


Eligibility criteria:
inclusion criteria: * patient 75 years or older * hospitalized in the geriatric perioperative unit for a femoral neck fracture between 18/11/2019 and 30/06/2021 * treated with a curative anticoagulant at entry * patient enrolled in or receiving a social security plan exclusion criteria: * orthopedic patient housed in the geriatric perioperative unit * patient who objected to the use of their data

Keywords: older patients anticoagulant femoral neck fractures clinical pharmacy service
study of rituximab plus high-dose chemotherapy non-hodgkin's lymphoma

Conditions: Lymphoma, Non-Hodgkin's

Summary: this study is being conducted to determine the safety, side effects, and response to a combination of an established high-dose chemotherapy regimen, plus the addition of rituximab (which is a form of immunotherapy).

combination chemotherapy is the standard treatment as initial therapy for advanced stage aggressive non-hodgkin's lymphoma (nhl). standard chemotherapy cures less than 40% of patients. when patients relapse, they may be eligible to receive high-dose chemotherapy with autologous stem cell support. multiple studies have shown the value of high-dose chemotherapy, with increased disease-free survival and overall survival, when compared with second-line conventional chemotherapy. unfortunately high-dose chemotherapy is curative in less than half the patients who receive it, and other treatment strategies are needed to improve the cure rate. another treatment option called immunotherapy is being tested in lymphoma patients. immunotherapy involves attempts to use the immune system or products of the immune system to fight lymphoma. for example, nhl cells have a protein called cd20 on their surface. rituximab is an antibody directed against the cd20 protein, which may result in the death of the lymphoma cell. patients in this study will receive rituximab to see if it is a safe treatment option for nhl patients.

Eligibility criteria:
inclusion criteria: * histologically documented, aggressive and/ or intermediate grade and high-grade b cell nhl, cd20 positive. * in relapse after primary conventional chemotherapy * tumor sensitive (at least a partial response) to induction chemotherapy and/ or radiation therapy after treatment for relapse * treatment of cns or meningeal disease (cytology-negative csf) if present * treatment of cns or meningeal disease (cytology-negative csf) if present. * cumulative total doxorubicin dosage \<500 mg/m2 * performance score: 0-2 * prior malignancies eligible if treated for cure and without active disease * patients must not be pregnant or nursing. * prior immunotherapy is allowed * signed informed consent * absolute neutrophil count \> 1500/ µl, platelet count \>100,000/ µl * bilirubin \<1.5 x normal, sgot \<2.5 x normal * serum creatinine \<1.5 mg/dl * ejection fraction \> 45% or \> 40% with normal wall motion * hiv negative * fev1, dlco \> 50% predicted exclusion criteria: * pregnant or nursing